(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Pfizer rolled out the first round of new data since it closed on Xtandi-maker Medivation in September—and the results weren’t good. The blockbuster prostate cancer med fell short in a trial that might ...
TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...
If Credit Suisse’s KOLs are correct about prostate cancer drug Xtandi’s latest clinical trial news, a change could be afoot for rival prostate drug Zytiga, which is sold by Johnson & Johnson’s Janssen ...
About XTANDI® (enzalutamide) and Important Safety Information XTANDI (enzalutamide) is an androgen receptor inhibitor indicated in the U.S. for the treatment of patients with castration-resistant ...
Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the company. The company’s flagship drug, ...
Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...
On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically ...
Research universities, many of them public, have joined forces with pharmaceutical companies and Wall Street firms to fight new government efforts to curtail out-of-control drug prices, saying the ...
With this approval, XTANDI is now the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant ...
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results